Xcel Pharma RECOHEAL | BPC-157 + TB-500

Xcel Pharma RECOHEAL | BPC-157 + TB-500

Xcel Pharma RECOHEAL combines two widely discussed research peptides, BPC-157 and TB-500, in a single formulation designed for research-focused applications involving tissue recovery, cellular signaling, and regenerative processes. This combination has attracted considerable interest within peptide research because BPC-157 and TB-500 are investigated for different but potentially complementary biological pathways.

What Is BPC-157?

BPC-157 is a synthetic peptide that has been investigated in preclinical research involving tissue repair, gastrointestinal biology, inflammation, vascular processes, and cellular signaling. Research interest surrounding BPC-157 has particularly focused on mechanisms associated with healing and tissue integrity.

Importantly, BPC-157 remains an investigational compound rather than an established approved human medicine. The FDA has stated that there is limited safety information for proposed routes of administration and has identified concerns including immunogenicity and peptide-related impurities.

What Is TB-500?

TB-500 is commonly described as a synthetic fragment related to thymosin beta-4. It has become a subject of research involving tissue repair, cellular migration, vascularization, and regenerative signaling.

The FDA’s current materials identify TB-500-related substances as subjects of evaluation for potential compounding and specifically note wound-healing as one of the uses evaluated. However, this should not be interpreted as FDA approval for treating injuries or other medical conditions. The FDA has also stated that it has not identified human exposure data for drug products containing TB-500 and has concerns regarding immunogenicity and peptide-related impurities.

Why Combine BPC-157 + TB-500?

RECOHEAL brings BPC-157 and TB-500 together to provide researchers with a convenient combination of two investigational peptides frequently discussed in regenerative and recovery-related research.

BPC-157 research has examined biological pathways associated with tissue integrity and repair, while TB-500-related research has investigated processes involving cellular movement, vascular development, and tissue-repair signaling. Studying the two compounds together can therefore be of interest when investigating overlapping regenerative mechanisms.

However, research interest should not be confused with proven clinical effectiveness. Human evidence for these compounds remains limited, and there is not enough high-quality clinical evidence to establish that the combination provides a specific therapeutic benefit in people.

Research Areas

BPC-157 and TB-500 have been investigated in different preclinical contexts, including:

• Tissue-repair mechanisms
• Cellular migration and signaling
• Vascular and angiogenic processes
• Connective-tissue research
• Inflammatory-response pathways
• Gastrointestinal research involving BPC-157
• Regenerative biology
• Wound-healing research involving TB-500

These areas represent research topics rather than approved medical indications. The FDA’s July 2026 advisory-committee materials specifically list ulcerative colitis as a use evaluated for BPC-157-related substances and wound healing as a use evaluated for TB-500-related substances.

Research-Focused Formulation

Xcel Pharma RECOHEAL is positioned as a research peptide combination for individuals or laboratories interested in studying BPC-157 and TB-500 together. Combining the compounds into one product may offer a practical format for research protocols where both peptides are being investigated.

Because peptide quality can depend on identity, purity, manufacturing practices, storage, and handling, researchers should evaluate appropriate documentation and analytical information for any research material before use.

Important Regulatory Information

BPC-157 and TB-500 should not be presented as FDA-approved treatments. FDA approval requires evidence demonstrating that a medicine is safe and effective for its intended use.

BPC-157 is also prohibited by the World Anti-Doping Agency under its non-approved substances category, while TB-500 is listed under prohibited growth factors and related substances. Competitive athletes should therefore verify their applicable anti-doping rules before exposure to either compound.

Storage and Handling

Research peptides should be handled according to the manufacturer’s specifications and appropriate laboratory procedures. Maintaining suitable storage conditions and minimizing unnecessary exposure to heat, light, moisture, and contamination can help preserve research-material integrity.

Specific reconstitution, dosing, administration, or human-use instructions should not be inferred from a product description. Such decisions require appropriate professional and regulatory oversight.

Xcel Pharma RECOHEAL — Key Highlights

• Product: Xcel Pharma RECOHEAL
• Composition: BPC-157 + TB-500
• Category: Research peptide combination
• Primary research interest: Regenerative and tissue-repair biology
• BPC-157 research: Tissue integrity, gastrointestinal and cellular pathways
• TB-500 research: Cellular migration, vascular and tissue-repair pathways
• Format: Combination research formulation

Disclaimer

Xcel Pharma RECOHEAL containing BPC-157 and TB-500 is described for research purposes and is not presented as a drug, dietary supplement, or approved treatment for any disease or medical condition. BPC-157 and TB-500 are investigational compounds, and their safety and effectiveness for human therapeutic use have not been established. Do not use this product for self-treatment, diagnosis, prevention, or treatment of any medical condition. Researchers should follow applicable laws, institutional requirements, manufacturer documentation, and appropriate laboratory safety procedures.